Key result
Five different inhibitors of the Ubiquitin Proteasome System blocked myofibril assembly at the nascent myofibril stage in both avian and human cardiomyocytes.
Why the study?
To determine whether human cardiomyocytes derived from human inducible pluripotent stem cells follow the same three-step myofibril assembly pathway seen in other model organisms.
Do Ubiquitin Proteasome System inhibitors block myofibril assembly in human and avian cardiomyocytes?
Do Ubiquitin Proteasome System inhibitors block myofibril assembly in human and avian cardiomyocytes?
Inhibition of the Ubiquitin Proteasome System blocks the maturation of myofibrils in cardiomyocytes, offering a mechanistic explanation for the cardiotoxicity of proteasome inhibitors used in multiple myeloma.
No takes yet. Share an insight, caveat, or question.
UPS inhibition may block cardiomyocyte myofibril maturation; leaves open its role in clinical cardiotoxicity of proteasome inhibitors.
Wang et al. (2021) studied this question. Ubiquitin Proteasome System (UPS) inhibitors was evaluated on Myofibril assembly progression. Five different inhibitors of the Ubiquitin Proteasome System blocked myofibril assembly at the nascent myofibril stage in both avian and human cardiomyocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: